Allogeneic stem-cell transplantation (SCT) is a potentially curative therapy for lymphoid malignancies. Myeloablative conditioning is associated with high non-relapse mortality (NRM). Reduced-intensity condition (RIC) reduces NRM but relapse rate is increased. Novel regimens with intensive anti-malignancy activity but limited toxicity are of benefit. We evaluated outcomes of 144 lymphoma patients given allogeneic SCT with RIC consisting of fludarabine and treosulfan (FT, n = 50), intravenous-busulfan (FB2, n = 38) or melphalan (FM, n = 56). Sixty-nine patients (48%) had chemo-sensitive disease and 75 (52%) had chemo-refractory disease at SCT. The median follow-up is 39 months (4-149). Three-year survival was 67, 74 and 48% after FT, FB2 and FM, in chemo-sensitive disease (P = 0.14) and 34, 11 and 17% in chemo-refractory disease, respectively (P = 0.08). Three-year NRM was 24, 24 and 54% (P = 0.002), whereas relapse mortality was 22, 34 and 18%, respectively (P = 0.13). Multivariate analysis identified a high comorbidityscore, chemo-refractory disease and FM as associated with shortened survival. In conclusion, FB2 is associated with low NRM and good results in chemo-sensitive disease, but with higher relapse mortality rates. FM controls disease better, but with high NRM. FT probably balances these outcomes more optimally. It is as safe as FB2 and as cytoreductive as FM, resulting in improved outcome, mostly in advanced disease. 
INTRODUCTION
High-dose chemotherapy and autologous stem cell transplantation (SCT) is the standard therapy for chemo-sensitive relapsed/ refractory aggressive lymphoma as well as Hodgkin's lymphoma. 1 Allogeneic SCT is usually reserved for patients who have failed a prior autologous SCT or possibly for patients considered at high risk of failing an autologous SCT. For some histologies, such as follicular lymphoma or T-cell lymphoma allogeneic SCT may be used upfront.
2 Standard myeloablative conditioning (MAC) has been historically associated with prohibitive rates of non-relapse mortality (NRM) in patients with lymphoma, in the range of 40-50% in most studies. [3] [4] [5] [6] [7] [8] Even higher rates, as high as 50-85%, have been reported in patients with comorbidities or a prior autologous SCT. [9] [10] Therefore, allogeneic SCT was limited to very selected patient groups. Reduced intensity (RIC) and nonmyeloablative (NMA) conditioning regimens have allowed marked reduction in NRM and extension of the indications and patient groups able to tolerate treatment. [11] [12] [13] [14] [15] [16] [17] More than two thirds of patients with lymphoid malignancies are currently offered these regimens. 18 Although patients with myeloid malignancies are often selected for RIC based on age, comorbidities and disease status, 19 patients with lymphoid malignancies are often selected for RIC based on the disease type alone. However, dose intensity is important in predicting outcome in lymphoid malignancies as well. Most studies have shown increased relapse rates after RIC/NMA compared with MAC, resulting in similar survival. [20] [21] [22] [23] [24] [25] [26] Novel conditioning regimens which will preserve the disease control effect of MAC but will be associated with acceptable patterns of toxicity and maintain the graft-versus lymphoma effect, will be of benefit.
Treosulfan is a prodrug of a bifunctional alkylating agent produced in-vivo in a non-enzymatic reaction. Preclinical studies demonstrated that treosulfan has intense activity against several malignancies. 27 The combination of fludarabine and treosulfan (FT) has been introduced over the last few years as a relatively dose-intensive regimen with favorable toxicity, mostly in patients with myeloid malignancies (reviewed in Danyelsko et al. 28 ). We have compared FT with busulfan based RIC or MAC regimens in patients with AML and myelodysplastic syndromes. 29 FT was associated with similar NRM as RIC, but controlled leukemia better, resulting in better outcome in patients with advanced disease at SCT. There are only limited data on the use of FT in lymphoid malignancies. 30, 31 In this study we report the outcomes of a prospective study of FT conditioning in patients with lymphoid malignancies and compare them to outcomes following the more commonly used busulfan and melphalan based RIC regimens.
PATIENTS AND METHODS

Patient eligibility
The study included 50 patients with various lymphoid malignancies given FT and allogeneic SCT on a phase II prospective study. Outcomes following SCT were compared retrospectively with an historical control group of 94 patients given a RIC regimen of fludarabine and reduced-dose busulfan (FB2) or fludarabine and melphalan (FM) before SCT, over a 13-year period. Some of the patients were included in a previous publication. 32 Patients were eligible for allogeneic SCT based on standard hematological criteria. 33 Patients with aggressive lymphoma and Hodgkin's lymphoma were most often eligible for allogeneic SCT after failure of a prior autologous SCT.
Patients with low-grade or transformed lymphoma and patients with T-cell lymphoma could have had allogeneic SCT upfront. Patients with chronic lymphocytic leukemia and patients with lymphoblastic or Burkitt's lymphoma were not included. All patients with lymphoid malignancies were eligible for a reduced-intensity conditioning. The minority of patients who had myeloablative conditioning were not included in this analysis.
Comorbidities were scored according to the Sorror hematopoietic cell transplantation comorbidity index (HCT-CI). The status of disease pre transplant was evaluated according to the Cheson revised response criteria. 34 Chemo-sensitive disease was defined as any complete or partial response. Chemo-refractory disease was defined as stable or progressive disease.
HLA typing was based on high-resolution typing of class I and class II HLA antigens. Patients had to have an HLA-compatible (matched or one antigen mismatched) related or unrelated donor willing to donate G-CSF mobilized peripheral blood stem-cells (the preferred requested option) or bone marrow. All patients were treated according to protocols that were approved by the institution review-board and gave written informed consent for their intended protocol. The prospective FT study was registered at ClinicalTrial.gov as NCT01079013.
Conditioning regimens
The FT regimen consisted of fludarabine (30 mg/m 2 on days − 6 to − 2) combined with treosulfan (10-12 gr/m 2 on days − 6 to − 4). The FB2 regimen consisted of fludarabine (30 mg/m 2 on days − 6 to − 2) combined with intravenous busulfan (3.2 mg/kg daily on days − 4 to − 3). The FM regimen consisted of fludarabine (30 mg/m 2 on days − 6 to − 2) combined with melphalan (50-70 mg/m 2 on day − 3 and − 2). Patients with an unrelated or mismatched donor were also given antithymocyte globulin (ATG, Fresenius, Graefelfing, Germany, 5 mg/kg given on days − 3 to − 1). Protocol assignment was not randomized and was affected to some degree by prior therapy and protocol priorities at the time of enrollment and also by the attending physician discretion. Phenytoin was administered before and until 24 h after completion of busulfan administration. Prophylaxis against GvHD consisted of cyclosporine A and a short course of methotrexate (15 mg/m 2 on day 1 and 10 mg/m 2 on days 3 and 6). GvHD prophylaxis was administered for 3 months and tapered afterwards in patients with no active GvHD. GvHD prophylaxis did not differ between the regimens. G-CSF was administered in all patients from day +7 until engraftment, by institutional guidelines. A standard institutional regimen of antibiotic prophylaxis was used to prevent bacterial, viral, fungal and pneumocystis carini infections.
Evaluation of response
Neutrophil and platelet engraftment were defined as the first of 3 days with an absolute neutrophil count 40.5 × 10 9 /L and the first of 7 days with an untransfused platelet count420 × 10 9 /L, respectively. Toxicity after SCT was graded by the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE, version 4). Acute and chronic GvHD were graded and staged by the National Institutes of Health consensus criteria. Chimerism was tested using FISH with X and Y chromosome probes in sexmismatched transplants and with PCR analysis of microsatellite markers in sex-matched transplants. Chimerism was tested in whole blood/marrow cells. Chimerism analysis within cell subsets was not performed. Mixed chimerism was defined as o95% donor chimerism. Response and relapse were determined by positron emission tomography and computerized tomography. Abbreviations: autoSCT = autologous SCT given before the current allogeneic SCT; DLCL = diffuse large B-cell lymphoma; FB2 = fludarabine and reduced dose (2 days) of intravenous busulfan; FM = fludarabine and of melphalan; FT = fludarabine and treosulfan; HCT-CI = hematopoietic cell transplantation comorbidity index; HL = Hodgkin's lymphoma; MUD = matched unrelated donor; NHL = non-Hodgkin's lymphoma; SCT = stem cell transplantation; TX = treatment.
Statistical analysis
Patient characteristics were compared between groups by Student t-test or one-way analysis of variance for continuous variables, and χ 2 test for categorical variables. Overall survival (OS) was calculated from the day of SCT until death or last follow-up. The probability of OS was estimated using the Kaplan-Meier method. 35 Relapse and NRM rates were estimated using cumulative incidence analysis and considered as competing risks. 36 In the analysis of the cumulative incidence of GvHD, relapse was considered a competing risk. The effect of various patient and disease categorical variables on survival probabilities was studied with the log-rank test. Cumulative incidence rates were compared by Gray test. Rates are presented with 95% confidence intervals (CI). A Cox proportional hazard model was used to determine the significance of multiple variables in determining these outcomes. Factors found with at least borderline significance (Po0.2) in the univariant analysis were included in the model. The conditioning regimen used was always included as its role was the major goal of the analysis. All P-values are two-sided and values o 0.05 were considered statistically significant. Statistical analyses were performed with SPSS 21.0 (SPSS Inc., Chicago, IL, USA) and R2.14.2 software packages (R Development Core Team, Vienna, Austria).
RESULTS
Patient and donor characteristics
The study included 144 patients with lymphoid malignancies following allogeneic SCT. One hundred and fifteen patients had non-Hodgkin's lymphoma including diffuse large B-cell lymphoma (n = 32), aggressive lymphoma transformed from low-grade lymphoma (n = 24), mantle cell (n = 17), low grade (n = 20) and T-cell lymphoma (n = 22). Twenty-nine patients had Hodgkin's lymphoma. Patient characteristics are outlined in Table 1 . The median age was 52 years (range, 16-69). Sixty-nine patients (48%) had chemo-sensitive disease at SCT (43 complete and 26 partial response) and 75 patients had chemo-refractory disease (5 stable disease and 70 progressive disease). Eighty-one patients (56%) were transplanted from sibling donors (HLA typing in one of them showed a one antigen mismatch). Sixty-three patients were given unrelated donor grafts that were 10/10 HLA matched in 47 patients and 9/10 matched in 16 patients. Eighty-seven patients (60%) had a prior autologous SCT. The median number of prior lines of therapy was 3.5 (range, [1] [2] [3] [4] [5] [6] [7] [8] . The preparative regimen included FT (n = 50), FB2, (n = 38) or FM (n = 58). As FT was only Table 1 ). The only other significant difference between the groups was the incidence of a prior autologous transplant. Thirty-four percent of the patients in the FM group had a prior autologous transplant compared with 82% in the FB2 group and 76% in the FT group (P o 0.001). There was no difference between the groups in median age, gender, donor, HCT-CI, disease type, number of prior therapies and status at SCT.
Engraftment and chimerism
One hundred and thirty-one patients achieved primary engraftment. Twelve patients (8%) died before engraftment and one patient in the FM group rejected the graft. This patient had a second transplant from the same sibling donor and engrafted. The causes of pre-engraftment deaths were organ failure (n = 8) and infections (n = 4). The median time to absolute neutrophil Abbreviations: DAH = diffuse alveolar hemorrhage; FB2 = fludarabine and reduced dose (2 days) of intravenous busulfan; FM = fludarabine and of melphalan; FT = fludarabine and treosulfan; NIH = National Institutes of Health; TMA = thrombotic microangiopathy. a toxicity is graded by NCI common toxicity criteria. Only patients with ⩾ 3 toxicity are presented. Some patients had toxicity in more than one organ system. b GvHD graded by NIH consensus criteria. /L, whereas all other patients became thrombocytopenic after conditioning.
There was no significant difference in chimerism kinetics. At one month after SCT, 97% of FT recipients had complete donor chimerism (495% donor). Similar rates were seen in FB2 and FM recipients, 96 and 93% had complete chimerism, respectively (P = 0.66). There was no difference between the regimens in chimerism at 3 months after SCT.
Toxicity and GvHD NCI CTC Grade III-V organ toxicity occurred in 21 FT recipients (42%) and in 15 (39%) recipients in the FB2 group compared with 37 patients (66%) in the FM group (P = 0.01). Hepatic toxicity and thrombotic microangiopathy were more prevalent in the FM group. Severe mucositis was relatively rare after FB2, whereas renal and pulmonary toxicities were less frequent after FT, but these differences did not reach statistical significance (Table 2) .
Acute GvHD Grade II-IV occurred in six FT recipients, cumulative incidence 12% (95% CI, 6-25%). This rate was lower than after FB2, cumulative incidence 37% (95% CI, 24-56%) and after FM, cumulative incidence 34% (95% CI, 24-49%) (Table 2), P = 0.007. The cumulative incidence rates of acute GVHD grade III-IV were also lower after FT compared with FB2 and FM; 2%, 13% and 20%, respectively (P = 0.001). Acute GvHD occurred later after FB2, median day of diagnosis, day 69 (range, 19-180) compared with Abbreviations: FB2 = fludarabine and reduced dose (2 days) of intravenous busulfan; FM = fludarabine and of melphalan; FT = fludarabine and treosulfan; HCT-CI = hematopoietic cell transplantation comorbidity index; HL = Hodgkin's lymphoma; HR = hazard ratio with 95% confidence intervals; MUD = matched unrelated donor; NHL = non-Hodgkin's lymphoma; NRM = non-relapse mortality at 3 years (No., total number; CI = cumulative incidence, rates are given with 95% confidence intervals, relapse was considered as a competing risk); HR = hazard ratio with 95% confidence intervals; MVA = multivariate analysis, factors were included in a Cox proportional hazard model; SCT = stem cell transplantation; TX = treatment.
day 31 (range, 16-66) and day 24 (range, 14-103) after FT and FM; respectively (P = 0.003). The cumulative incidence of chronic GvHD was similar among the different regimens, 36% (95% CI, 24-40), 37% (95% CI, 24-56) and 22% (95% CI, 14-37) after FT, FB2 and FM, respectively (P = 0.28). There was no difference in the severity of chronic GvHD or its pattern (classical or overlap types). NRM NRM occurred in 52 patients with a cumulative incidence of 35% (95% CI 28-44%) at 3 year after SCT. Twenty five patients died of organ toxicities, 11 patients died of complications related to acute GvHD, 4 due to chronic GvHD, 9 died of infections not in the context of active GvHD, 1 of graft failure, 1 of secondary malignancy and 1 of an accident. The 3-year NRM was 24% (95% CI, 14-41% ) after FT, 24% (95% CI, 13-42) after FB2 and 54% (95% CI, 42-68%) after FM, respectively (P = 0.002 Figure 1 ). Multivariate analysis determined that advanced age, HCT-CI ⩾ 3, chemo-refractory disease, unrelated donor and FM conditioning were the most significant factors associated with NRM with hazard ratios (HR) of 2.0 (P = 0.03), 4.1 (P = 0.0002), 2.0 (P = 0.03), 2.1 (P = 0.02) and 3.9 (P = 0.002), respectively (Table 3) .
Relapse mortality Thirty-four patients died of relapse after SCT, with a cumulative incidence of 25% (95% CI 18-34%) at 3 year after SCT. Table 4 outlines the uni-and multivariate analysis of factors predicting for relapse mortality. As expected, relapse mortality rates were significantly higher in patients with chemo-refractory disease. Abbreviations: FB2 = fludarabine and reduced dose (2 days) of intravenous busulfan; FM = fludarabine and of melphalan; FT = fludarabine and treosulfan; HCT-CI = hematopoietic cell transplantation comorbidity index; HL = Hodgkin's lymphoma; HR = hazard ratio with 95% confidence intervals; MUD = matched unrelated donor; NHL = non-Hodgkin's lymphoma; NRM = non-relapse mortality at 3 years (No., total number; CI = cumulative incidence, rates are given with 95% confidence intervals, relapse was considered as a competing risk); HR = hazard ratio with 95% confidence intervals; MVA = multivariate analysis, factors were included in a Cox proportional hazard model; SCT = stem cell transplantation; TX = treatment Relapse at 3-years (No., total number; CI, cumulative incidence, rates are given with 95% confidence intervals, non-relapse mortality was considered as a competing risk). *FB2 compared with FM/FT.
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The 3-year relapse mortality rate after FT was 22% (95% CI, 11-44) compared with 34% (95% CI, 22-53) and 18% (95% CI, 10-31) after FB2 and FM, respectively (P = 0.13 for FB2 vs FT/FM, Figure 2 ). When adjusting for patient characteristics the multivariate analysis showed that FT was associated with a trend for lower relapse mortality rates, HR 0.5 (P = 0.16). Chemo-refractory disease was the most important factor with a HR of 11.1 (P o 0.001). Female gender was associated with a higher incidence of relapse mortality, HR 3.8 (P = 0.001).
Outcome With a median follow-up of 39 months (4-149), 58 patients are alive and 86 have died. Fifty-two patients died of treatmentrelated complications and 34 of disease relapse. Eleven patients are alive following various therapies for relapse. The actuarial 3-year OS is 40% (95 CI 30-49%). Table 5 outlines the univariate and multivariate analysis of factors influencing outcome. Univariate analysis identified disease status at SCT and HCT-CI as the most significant predictors of outcome. Patients with chemo-sensitive disease had an OS of 62% (95 CI 50-75%), whereas patients with chemo-refractory disease had an OS of 20% (95 CI 10-30%, P o0.001). Patients with HCT-CIo 3 had an OS of 45% (95% CI 36-54%), whereas patients with HCT-CI ⩾ 3 had an OS of 9% (95% CI 0-24%, P = 0.001).
Better OS was observed after FT in the univariate analysis but it was equivalent to FB2 and better than FM in the multivariate analysis (Figure 3a) . Multivariate analysis confirmed the adverse effect of chemo-refractory disease (HR 2.7, P = 0.001), HCT-CI ⩾ 3 (HR 2.8, P = 0.001), and FM (HR 1.8, P = 0.05) as independent adverse factors for survival. There was a trend for better survival in transplants performed in recent years in the univariant analysis, but it did not remain significant after adjusting for other variables (Table 5 , HR 1.0).
There was no statistical difference in OS within the chemosensitive group between the three different regimens (67% after FT, 74% after FB2 and 48% after FM, P = 0.14, Figure 3b ). However, in the chemo-refractory group FT showed a trend for better OS of 34% compared with 11% with FB2 and 17% with FM with borderline statistical significant (P = 0.08, Figure 3c) .
DISCUSSION
In the current study, we explored three different conditioning regimens for allogeneic SCT in patients with lymphoma. FT, a more recently introduced regimen was compared with FB2 and FM, more widely used RIC regimens. Bacigalupo et al defined the dose intensity of a conditioning regimen based on the reversibility and expected duration of cytopenia after SCT. 37 However, regimens that are considered to be of the same group intensity, such as the three regimens used in this study, may be associated with different outcomes. We have previously compared FB2 and FM in a group of 151 patients with various hematologic malignancies after allogeneic SCT. 32 FM was more myelosuppressive. It was associated with higher rates of acute GvHD and NRM but with better disease control than FB2. Similar results were more recently reported by an European Blood and Marrow Stem Cell Transplantation Group study in patients with AML. 38 NRM rates are exceedingly high after MAC in lymphoma patients even in the modern era. 23, 24 NRM is lower after RIC, in the range of 20-35%, which is still higher than NRM after RIC in AML/myelodysplastic syndromes. [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] This is possibly related to patients with lymphoma been older and more heavily treated at the time of SCT including a high incidence of prior autologous SCT. In the current study NRM was relatively low after FT and FB2, both 24%, similar to RIC regimens, whereas it was 54% after FM which is more similar to MAC regimens. However, this should be taken with caution due to small subset numbers. Acute GvHD rates after FT were relatively low as previously reported in AML/myelodysplastic syndromes patients. This is probably due to less tissue damage and in particular less mucositis after FT and a less supportive cytokine release pattern. 39 However, chronic GvHD rates are similar after FT and other RIC or MAC regimens. 29, 40 Similar to other studies advanced age, comorbidities, unrelated donor and chemo-refractory disease were also associated with higher NRM.
Relapse rates are higher after RIC than MAC in most studies. In the current study relapse mortality rates were relatively low after FT and FM, 22% and 18%, respectively, compared with 34% after FB2. Chemo-refractory disease at SCT was the most important factor to predict relapse mortality. Thus, it seems FT is associated with NRM similar to FB2 and other RIC, whereas relapse mortality rate is lower, similar to FM and MAC. This may translate into improved survival. 3-year OS was 54, 42 and 29% after FT, FB2 and FM, respectively (P = 0.01); however, remained significant in the multivariate analysis only for worse outcome with FM. In all, adverse prognostic factors for OS included in addition to FM conditioning, chemo-refractory disease and a high comorbidity score. Disease histology and a prior autologous SCT were not adverse factors.
In the largest series of patients with lymphoma of various histologies (aggressive-668, indolent-580), reported by the Center of International Bone Marrow Transplant Research the 3-year OS was 54% for age of 40-54 years, 40% for age 55-65 and 39% for age ⩾ 65 years. 11 Advanced age, poor performance status, disease status and donor HLA mismatching affected survival. This was similar to the current study, however, HLA mismatching in our study, though limited in numbers, did not predict worse outcome (data not shown). Survival rates in the range of 20-52% have been reported in other, smaller studies depending on patient characteristics at SCT. [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] Chemo-refractory disease is the most important predicting factor for survival across all studies. However, a small subset of patients with refractory lymphoma can achieve long-term survival with allogeneic SCT with both MAC and RIC. The Center of International Bone Marrow Transplant Research reported on 533 patients with chemo-refractory aggressive or follicular lymphoma. 22 The 3-year OS was 19 and 28% after RIC and MAC, respectively (P = NS). The results of MAC were offset by excessive NRM. Allogeneic SCT may be able to overcome partial refractory lymphoma, such as partial response or stable disease at SCT, but probably not truly progressive disease. 2 In the current study, FT resulted in a 3-year OS of 34% in patients with refractory disease that was better than that achieved with FB2 or FM, 11 and 17%, respectively. Although, outcome seems somewhat better with FT, results of patients with chemo-refractory disease are still dismal, and new approaches are still needed in this setting. Disease histology is a predictor of outcome in some, but not all studies. Indolent lymphoma is usually associated with better outcome due to more effective graft-versus lymphoma effect and a lesser need for intensive chemotherapy to control disease until it becomes effective. 15 Patients with diffuse large B-cell lymphoma, who relapse after autologous SCT have a very poor prognosis with standard chemotherapy. Responses are not common, short and 1-year survival is 11%. 41, 42 Recent reports show that allogeneic SCT can induce long-term survival in 40-50% of patients. [23] [24] The prognosis of patients with Hodgkin's lymphoma who relapse after autologous SCT is also poor. MAC was historically associated with very high NRM but about 15-20% were cured. 7, 8 Like nonHodgkin's lymphoma, dose intensity does matter and relapse rates are higher after RIC and NMA. 43 Twenty to fifty percent of these patients may enjoy long-term survival following allogeneic SCT with RIC depending on disease status at SCT. We could not assess the impact of the different regimens in the histological subtypes due to low numbers.
Prior autologous SCT was associated with outcome in some 11, 20 but not all studies. 13, 16, 22, 23 Most patients with aggressive lymphoma would have had an autologous SCT before allogeneic SCT, and this is a major indication for selection of RIC. Patients Abbreviations: autoSCT = autologous SCT given before the current allogeneic SCT; FB2 = fludarabine and reduced dose (2 days) of intravenous busulfan; FM = fludarabine and of melphalan; FT = fludarabine and treosulfan; HCT-CI = hematopoietic cell transplantation comorbidity index; HL = Hodgkin's lymphoma; MUD = matched unrelated donor; NHL = non-Hodgkin's lymphoma; OS = overall survival at 3 years (No., total number; Kaplan-Meier estimated incidence, rates are given with 95% confidence intervals); SCT = stem cell transplantation; TX = treatment.
Treosulfan vs other RIC in lymphoid malignanciesgiven FM had a worse outcome despite including a lower proportion of prior autologous SCT. This was due to higher rates of acute GvHD and organ toxicity with this regimen. The same observations were seen when the analysis was limited to only patients with a prior autologous SCT (data not shown). The similar outcome of patients with and without prior autologous SCT is probably due to the reduced toxicity with RIC regimens. The current study has several limitations. The major endpoint of this study was the safety and outcomes of FT in lymphoid malignancies. To put these results in perspective we compared these outcomes with a historical control group given other RIC regimens. This comparison needs to be taken with caution as it may be associated with several statistical flaws. Although patients given FT were enrolled prospectively, the analysis and comparison with FB2 and FM is retrospective. There may be some differences in data collection between the prospective and retrospective parts of the analysis. FT recipients were also treated more recently. Supportive care techniques have improved in recent years, however, when adjusting for other variables, the time of SCT was not predicting in the current study NRM or OS. Patient assignment was not randomized, but was determined at the attending physician's discretion that may have been biased to some extent by patient characteristics and prior therapy. The study also included a heterogeneous group of disease histologies and disease status at SCT and the total number of patients is relatively limited. Thus, certain differences in patient characteristics may affect outcome without being statistically significant. A larger proportion of patients with diffuse large B-cell lymphoma were allocated to FB2, which may be too less intensive for an aggressive malignancy and this may bias against FB2. Notwithstanding these limitations certain conclusions can be suggested. Dose intensity is important in lymphoid malignancies to a similar extent to myeloid malignancies. MAC is associated with prohibitive NRM, but mostly in patients with comorbidities or a prior autologous SCT. 44 Fit patients with low risk of NRM, and in particular if not in complete remission at SCT, should be considered for more intensive conditioning. RIC can be curative in patients with various lymphoid malignancies including patients relapsing after autologous SCT. Different RIC regimens that may be considered dose intensity equivalent may result in substantial differences in SCT outcome. The FB2 regimen is associated with low NRM and good results in patients with chemo-sensitive disease, but is possibly less intensive with higher relapse rates. The FM regimen controls the disease better, but is associated with high NRM and lower survival. The recently introduced FT regimen probably balances these outcomes more optimally. It has a safety profile that is similar to FB2 and efficacy profile that is similar to FM, thus resulting in improved overall outcome, mostly in patients with active disease at SCT.
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